HK Stock Market Move | TENNOR THERAP-B (06872) rises nearly 3%; recently entered into a supplementary agreement to the exclusive commercialization cooperation agreement with Grand Life Sciences
TENNOR THERAP-B (06872) rose nearly 3%, up 2.43% as of press time to HK$69.5, with a turnover of HK$3.5779 million.
TENNOR THERAP-B (06872) rose nearly 3%, up 2.43% as of press time to HK$69.5, with turnover of HK$3.5779 million.
On the news front, TENNOR THERAP-B announced that the company has been actively advancing the China marketing authorization review process for the first indication of rifasutenizol and the corresponding commercialization preparations. To align with the relevant review process, ensure that the cooperation arrangements are consistent with the expected commercialization timeline of rifasutenizol, and further consolidate the long-term cooperative relationship between the company and Grand Life Sciences, the board of directors is pleased to announce that on November 12, 2026, the company entered into a supplementary agreement to the cooperation agreement with Grand Life Sciences.
Accordingly, both parties agreed to extend the relevant period under the cooperation agreement during which Grand Life Sciences has the right to unilaterally terminate the cooperation agreement by written notice due to the company's failure to obtain the China marketing authorization for the first indication of rifasutenizol by the specified date, from December 31, 2026 to July 31, 2027.
Related Articles

HK Stock Market Move | CSTONE PHARMA-B (02616) rose over 11% in the afternoon; the company plans to initiate the global Phase III registrational clinical trial of CS2009 by the end of 2026.

No Human Intervention Needed! JPMorgan (JPM.US) Teams Up with Hyundai Card to Explore Autonomous Financial Transactions by AI Agents

HAITONG INT'L: Cuts Eastroc Beverage (09980) target price to HK$123, maintains "Outperform" rating
HK Stock Market Move | CSTONE PHARMA-B (02616) rose over 11% in the afternoon; the company plans to initiate the global Phase III registrational clinical trial of CS2009 by the end of 2026.

No Human Intervention Needed! JPMorgan (JPM.US) Teams Up with Hyundai Card to Explore Autonomous Financial Transactions by AI Agents

HAITONG INT'L: Cuts Eastroc Beverage (09980) target price to HK$123, maintains "Outperform" rating






